GC Biopharma and Thai Red Cross Sign MOU to Enhance Plasma Therapies

GC Biopharma has formalized a partnership with the Thai Red Cross Society (TRCS) by signing a Memorandum of Understanding (MOU) on August 14, 2025. This agreement aims to bolster collaboration in the field of plasma-derived therapies, focusing on training and technology transfer initiatives that will enhance Thailand’s capacity in plasma fractionation.

The new partnership builds on a longstanding relationship established in 2015 when GC Biopharma played a pivotal role in the creation of Thailand’s plasma fractionation facility. The MOU outlines plans for developing training and exchange programs that will facilitate the transfer of advanced manufacturing technologies. This initiative is expected to significantly strengthen local capabilities in producing plasma-derived medicinal products.

Objectives and Benefits of the Partnership

Hyoungjun Park, Vice President of GC Biopharma, emphasized the importance of this MOU, stating, “This agreement is a vital step in expanding advanced technology across Asia while contributing to public welfare.” The collaboration is set to enhance human resource development, improve product quality and safety, and ultimately contribute to public health security in Thailand and the surrounding region.

Assoc. Prof. Dootchai Chaiwanichsiri, Director of the National Blood Centre at TRCS, echoed this sentiment, highlighting that the partnership will play a crucial role in advancing both workforce development and technology transfer. The initiative aligns with Thailand’s ongoing efforts to enhance its healthcare infrastructure and capabilities, particularly in the realm of blood-derived therapies.

Strategic Expansion of GC Biopharma

GC Biopharma’s decision to pursue this collaboration reflects its broader strategy to expand its plasma-derived therapeutics business. The company made significant strides by entering the U.S. immunoglobulin market in 2024 and is actively seeking partnerships across Southeast Asia. This region has been identified as a key area for developing domestic fractionation capacity, which is vital for meeting local healthcare needs.

The company’s focus on strengthening its presence in Southeast Asia underscores the growing importance of plasma-derived therapies in addressing public health challenges. Through this partnership with the Thai Red Cross, GC Biopharma aims not only to enhance its operational capabilities but also to contribute significantly to the welfare of communities in Thailand and beyond.

As both organizations move forward with the MOU, the anticipated outcomes include a more robust healthcare system equipped to produce high-quality plasma-derived products, supporting the overall health security of the region. This collaboration is poised to set a precedent for similar initiatives in other countries, fostering a global approach to enhancing the production and availability of essential therapies.